

## *Supporting information*

### **Gold-based paper for antigen detection of monkeypox virus**

Liya Ye<sup>a,b</sup>, Xianlu Lei<sup>a,b</sup>, Xinxin Xu<sup>a,b\*</sup>, Liguang Xu<sup>a,b</sup>, Hua Kuang<sup>a,b</sup>, Chuanlai Xu<sup>a,b</sup>

<sup>a</sup>State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China;

<sup>b</sup>International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China;

\*Corresponding author. Email: xxx89826@163.com;


#### **Contents**

**Fig. S1.** Soluble expression of recombinant A29 protein. (A): M: The molecular weight standard of protein. 1: Supernatant induced at 37°C. 2: Precipitation induced at 37°C. 3: Ni<sup>2+</sup> affinity chromatography purification. (B): Gel filtration chromatography purification.

**Table S1.** Biological properties of MPXV-A29-specific mAbs generated in this study.

**Table S2.** The screening of the matched mAbs against A29 protein by the checkerboard method.

**Fig. S2.** Optimization of colloidal gold and antibody binding conditions. (A) The state of colloidal gold with different amount of antibody. (B) The state of colloidal gold at different pH value.




**Fig. S1.** Soluble expression of recombinant A29 protein. (A): M: The molecular weight standard of protein. 1: Supernatant induced at 37°C. 2: Precipitation induced at 37°C. 3: Ni<sup>2+</sup> affinity chromatography purification. (B): gel filtration chromatography purification.

**Table S1.** Biological properties of MPXV-A29-specific mAbs generated in this study.

| <b>mAbs</b> | <b>Isoytp</b> | <b>ELISA titer</b> |
|-------------|---------------|--------------------|
| 1D6         | IgG1          | 10 <sup>-5</sup>   |
| 2D2         | IgG1          | 10 <sup>-6</sup>   |
| 3D6         | IgG1          | 10 <sup>-4</sup>   |
| 4C7         | IgG1          | 10 <sup>-4</sup>   |
| 5D8         | IgG1          | 10 <sup>-5</sup>   |
| 6D12        | IgG2a         | 10 <sup>-4</sup>   |
| 7C5         | IgG1          | 10 <sup>-6</sup>   |
| 8F8         | IgG1          | 10 <sup>-6</sup>   |
| 9D8         | IgG1          | 10 <sup>-5</sup>   |
| 10F8        | IgG1          | 10 <sup>-4</sup>   |
| 11F5        | IgG1          | 10 <sup>-4</sup>   |
| 12G7        | IgG2b         | 10 <sup>-6</sup>   |
| 13G4        | IgG2a         | 10 <sup>-5</sup>   |
| 14F12       | IgG1          | 10 <sup>-5</sup>   |
| 15F11       | IgG1          | 10 <sup>-4</sup>   |
| 16C4        | IgG1          | 10 <sup>-5</sup>   |
| 17C9        | IgG1          | 10 <sup>-6</sup>   |
| 18A8        | IgG1          | 10 <sup>-6</sup>   |
| 19D11       | IgG2a         | 10 <sup>-5</sup>   |
| 20B8        | IgG2a         | 10 <sup>-4</sup>   |
| 21B4        | IgG1          | 10 <sup>-5</sup>   |
| 22D3        | IgG1          | 10 <sup>-5</sup>   |
| 23F3        | IgG2b         | 10 <sup>-6</sup>   |
| 24H2        | IgG1          | 10 <sup>-5</sup>   |
| 25C1        | IgG1          | 10 <sup>-4</sup>   |

**Table S2.** The screening of the matched mAbs against A29 protein by the checkerboard method.

| Gold lablled antibodies | Coated antibodies |     |     |     |       |       |      |      |
|-------------------------|-------------------|-----|-----|-----|-------|-------|------|------|
|                         | 3D6               | 5D8 | 7C5 | 8F8 | 14F12 | 15F11 | 20B8 | 25C1 |
| 3D6                     | -                 | -   | ++  | -   | +     | -     | -    | -    |
| 5D8                     | -                 | -   | +++ | -   | +     | +     | +    | -    |
| 7C5                     | +                 | -   | +   | +   | -     | -     | -    | +    |
| 8F8                     | +                 | -   | -   | -   | -     | -     | +    | -    |
| 14F12                   | -                 | -   | -   | -   | +     | -     | -    | +    |
| 15F11                   | +                 | -   | -   | -   | -     | -     | -    | +    |
| 20B8                    | -                 | -   | -   | -   | -     | -     | -    | +    |
| 25C1                    | ++                | ++  | -   | -   | -     | +++   | -    | +    |



**Fig. S2.** Optimization of colloidal gold and antibody binding conditions. (A) The state of colloidal gold with different amount of antibody. (B) The state of colloidal gold at different pH value.